To determine whether treatment with the calcium antagonist nimodipine would reduce neurological deficit in acute ischemic stroke patients.
- Nimodipine (Nimotop®)Drug
Other Names: The treatment group Intervention Desc: Calcium channel blocker (L-type calcium channels)
Prospective, single-blind, controlled trial of 60 patients at a single center.
Patients were randomized to receive nimodipine (120 mg/d in 3 divided doses) or standard treatment alone for 28 days. Standard treatment consisted of 10% depolymerized dextran 12h/d for 5 days. Digitalis, antihypertensive medication, antibiotics and heparin were administered as needed. Patients did not receive follow-up evaluations.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Mathew sum score on days 1, 2, 3, 5, 7, 14, 21, and 28 of treatment.|